Libtayo
E579610
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
Statements (40)
| Predicate | Object |
|---|---|
| instanceOf |
immunotherapy drug
ⓘ
monoclonal antibody ⓘ prescription medicine ⓘ |
| bindsTo | PD-1 receptor on T cells ⓘ |
| hasAdverseEffect |
diarrhea
ⓘ
endocrinopathies ⓘ fatigue ⓘ immune-related colitis ⓘ immune-related hepatitis ⓘ immune-related pneumonitis ⓘ rash ⓘ |
| hasATCClass | L01FF ⓘ |
| hasDrugClass |
PD-1 inhibitor
ⓘ
immune checkpoint inhibitor ⓘ |
| hasForm | concentrate for solution for infusion ⓘ |
| hasGenericName | cemiplimab ⓘ |
| hasMechanismOfAction |
blocks interaction between PD-1 and its ligands
ⓘ
enhances T-cell mediated immune response against tumors ⓘ |
| hasMolecularType | human monoclonal antibody ⓘ |
| hasPharmacologicalEffect |
antineoplastic effect
ⓘ
immunomodulating effect ⓘ |
| hasRouteOfAdministration | intravenous infusion ⓘ |
| hasTherapeuticArea |
dermatologic oncology
ⓘ
oncology ⓘ thoracic oncology ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| isIndicatedFor |
first-line treatment of certain non-small cell lung cancers
ⓘ
locally advanced basal cell carcinoma ⓘ locally advanced cutaneous squamous cell carcinoma ⓘ metastatic basal cell carcinoma ⓘ metastatic cutaneous squamous cell carcinoma ⓘ |
| isUsedFor |
advanced lung cancer
ⓘ
advanced skin cancer ⓘ basal cell carcinoma ⓘ cutaneous squamous cell carcinoma ⓘ non-small cell lung cancer ⓘ |
| isUsedIn | adult patients ⓘ |
| regulates | immune checkpoint signaling ⓘ |
| targets |
PD-1 pathway
ⓘ
programmed cell death protein 1 NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.